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Abstract:
Introduction: Each year, the US Antarctic Program rapidly transports scientists and support personnel from sea level (SL) to the South 
Pole (SP, 2835 m) providing a unique natural laboratory to quantify the incidence of acute mountain sickness (AMS), patterns of altitude 
related symptoms and the field effectiveness of acetazolamide in a highly controlled setting. We hypothesized that the combination of 
rapid ascent (3 hr), accentuated hypobarism (relative to altitude), cold, and immediate exertion would increase altitude illness risk.
Methods: Medically screened adults (N = 246, age = 37 ± 11 yr, 30% female, BMI = 26 ± 4 kg/m2) were recruited. All underwent SL 
and SP physiological evaluation, completed Lake Louise symptom questionnaires (LLSQ, to define AMS), and answered additional 
symptom related questions (eg, exertional dyspnea, mental status, cough, edema and general health), during the 1st week at altitude. 
Acetazolamide, while not mandatory, was used by 40% of participants.
Results: At SP, the barometric pressure resulted in physiological altitudes that approached 3400 m, while T °C averaged −42, humidity 
0.03%. Arterial oxygen saturation averaged 89% ± 3%. Overall, 52% developed LLSQ defined AMS. The most common symptoms 
reported were exertional dyspnea-(87%), sleeping difficulty-(74%), headache-(66%), fatigue-(65%), and dizziness/lightheadedness-
(46%). Symptom severity peaked on days 1–2, yet in .20% exertional dyspnea, fatigue and sleep problems persisted through day 7. 
AMS incidence was similar between those using acetazolamide and those abstaining (51 vs. 52%, P = 0.87). Those who used acetazol-
amide tended to be older, have less altitude experience, worse symptoms on previous exposures, and less SP experience.
Conclusion: The incidence of AMS at SP tended to be higher than previously reports in other geographic locations at similar altitudes. 
Thus, the SP constitutes a more intense altitude exposure than might be expected considering physical altitude alone. Many symptoms 
persist, possibly due to extremely cold, arid conditions and the benefits of acetazolamide appeared negligible, though it may have 
prevented more severe symptoms in higher risk subjects.
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Introduction
The physical altitude of the geographic South Pole 
(2835 m, 9300 ft) makes high altitude illness likely in 
polar workers, but the disease incidence and symptom 
patterns in this population are unknown. Polar workers 
undergo rapid air transport from McMurdo station 
(sea level) to the South Pole in 3–4 hours and often 
report directly to jobs that require physical exertion in 
extreme cold. Rapid exposure to high-altitude coupled 
with  immediate  physical  exertion,  low  barometric 
pressure, and the extremely cold, arid climate at the 
South Pole produce an intensified altitude exposure 
risk for polar workers.1
In  the  context  of  acute  exposure  to  hypobaric 
hypoxia, one or more well described high altitude 
syndromes  may  occur  during  the  initial  days  at  a 
new  elevation. Acute  mountain  sickness  (AMS)  is 
a syndrome typically arising in the first 1–2 days at 
a new altitude and is diagnosed by the presence of a 
headache along with sleep disturbance, gastrointestinal 
symptoms, fatigue, and dizziness or lightheadedness. 
High altitude cerebral edema, referred to as HACE, is 
a syndrome often diagnosed in the presence of acute 
mountain  sickness  when  mental  status  changes  or 
ataxia emerge. High altitude pulmonary edema, also 
known as HAPE, usually occurs after 2–4 days at 
altitude and may present rapidly in individuals with 
no signs of AMS. Each of these syndromes presents 
a health risk to polar workers and may significantly 
impair judgment or disrupt work productivity.
To mitigate these and other health risks, all workers 
in the United States Antarctic Program are medically 
screened prior to deployment. This screening marks 
polar workers as a unique, generally healthy cross 
section  of  the  population  in  which  to  observe  the 
physical effects of hypobaric hypoxia.
Antarctic workers have been the subject of occu-
pational  health  research,  but  the  health  effects 
encountered  by  workers  at  the  South  Pole  have 
not been studied in detail.2,3 In 2001, John B. West 
speculated that workers at the Amundsen-Scott South 
Pole Station in Antarctica might experience altitude 
illnesses  due  to  low  barometric  pressure,  extreme 
cold, and rapid transport and that these effects would 
be worse during the Antarctic winter when barometric 
pressures linger around 508 torr.4
West’s comments came after decades of intensive 
research had revealed reliable preventive measures 
for  the  most  commonly  encountered  high  altitude 
syndromes.5  It  is  clear  that  hypoxia  is  the  main 
physiologic  precursor  of  altitude  illnesses,  yet  the 
precise physiologic mechanisms for most high altitude 
illnesses remain a subject of investigation with an 
increased  focus  on  genetic  susceptibility.6,7  Field 
studies remain a favored approach for investigating 
the  effects  of  hypobaric  hypoxia  but  present 
unique  technical  challenges  in  subject  selection, 
exposure measurement, and interpretation of results. 
Consequently, field studies have generally been small, 
recruited  physically  fit  subjects,  and  have  utilized 
variable rates of ascent, final elevations, and global 
latitudes. To  overcome  these  challenges,  increased 
understanding  of  the  physiologic  interrelationships 
producing  high  altitude  illnesses  will  be  advanced 
by  larger,  well-controlled  field  studies  of  the 
general population involving rapid transport to high 
altitude.8,9
We  conducted  the Antarctic  Study  of Altitude 
Physiology (ASAP), a large multi-year field study 
of  United  States  Antarctic  Program  participants 
to  quantify  the  incidence  and  patterns  of  high 
altitude illnesses in polar workers. The study was 
conducted during the 50th anniversary of the United 
States Antarctic Program and concluded during the 
International Polar Year (2007–2008) capitalizing on 
the construction of the new Amundsen-Scott Station 
dedicated  on  January  1,  2009.  We  hypothesized 
that  the  incidence  of  high  altitude  illness  would 
be  greater  than  that  observed  in  other  studies  of 
rapid transport at similar elevations, and that there 
would be symptom pattern variability due to the low 
barometric pressures, cold working environments, 
and  arid  atmospheric  conditions  at  the  South 
Pole.  We  also  suspected  that  the  observed  field 
effectiveness  of  acetazolamide  in  this  population 
would  differ  from  its  demonstrated  efficacy  in 
placebo controlled clinical trials.
Methods
Two summer research expeditions to Antarctica were 
conducted during the 2006–07 and 2007–08 seasons 
with support from the National Science Foundation 
(NSF). The study was approved by the IRB at the 
Mayo Clinic in Rochester, Minnesota and all subjects 
gave  written  informed  consent  after  reviewing  the 
study protocol.Altitude illness in Antarctica
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Study participants
Each October, United States Antarctic Program par-
ticipants destined for summer work at the Amundsen-
Scott South Pole Station were recruited. Most jobs at 
SP require physical activity and a significant portion of 
personnel work outdoors. Typical activities included 
construction,  heavy  equipment  operation,  transport 
of supplies, science support and fuel delivery. After 
passing an extensive medical screen at home, these 
individuals arrived at McMurdo Station from destina-
tions around the United States. During both 2006 and 
2007, South Pole workers waited nearly two weeks 
at McMurdo station prior to the opening of the South 
Pole station.
Upon arrival at McMurdo station, polar workers 
received  a  flight  schedule  update  and  a  medical 
briefing regarding high altitude illnesses. Symptoms 
and  risks  were  explained  by  medical  staff  and 
prophylactic  acetazolamide  packets  were  made 
available. The study was then explained to the group 
and individuals were invited to enroll. For subjects 
that chose to take acetazolamide; they were given a 
packet with 10–250 mg tablets and instructed to begin 
taking  the  medication  24–48  hr  before  departure, 
twice daily. If they had any side effects from the 
medication, they were further instructed to reduce 
the dose to 125 mg BID.
Baseline questionnaire and symptom 
reporting
Participants answered a baseline medical questionnaire 
and received physiological testing (heart rate, blood 
pressure, arterial oxygen saturation-SaO2, blood draw 
for hemoglobin and hematocrit) at sea level and after 
their second night at altitude. Lake Louise Symptom 
Score questionnaires were completed at baseline, dur-
ing rapid ascent and for 7 days after arrival at the South 
Pole.  Subjects  also  answered  additional  symptom 
questions (not part of the Lake Louise Scoring   System) 
related to 1) shortness of breath at rest and on exertion, 
2) general health limitation, 3) mental status changes, 
4) cough and 5) peripheral edema.
The  baseline  medical  questionnaire  explored 
chronic medical conditions, current medications, pre-
vious altitude experience, lifestyle assessments (eg, 
smoking, alcohol use, exercise tendencies) and previ-
ous Antarctic experience. Job classification, activity 
levels, and medications were also coded for analysis.
Participants  submitted  nine  separate  symptom 
reports  labeled  Baseline,  PLANE,  Day  1,  Day  2, 
and Day 3, through Day 7. These symptom reports 
included the standard Lake Louise Symptom Score 
format plus the additional symptom questions noted. 
For each symptom, subjects could report none = 0, 
mild = 1, moderate = 2, or severe = 3. The sheet 
labeled BASELINE was completed soon after arrival 
to McMurdo, while the PLANE was completed on 
the polar flight, and Day 1 was completed prior to 
sleep on the day of arrival. Subjects were instructed 
to complete Days 2–7 immediately upon rising from 
sleep each day. The case definition for AMS utilized 
the standard Lake Louise Symptom Scoring System 
which requires the presence of a headache and an 
overall symptom score of 3 or greater.10
Workers were included in the study if they had 
assignments longer than one week at the South Pole. 
During 2007 we only included subjects who had not 
participated in our study during 2006.
Statistical analysis
Data were described as mean ± standard deviation, 
or count (percent). Chi-square and two sample t-tests 
were used to compare participant characteristics and 
symptoms among those who took acetazolamide and 
those abstaining. All tests were two-sided, P , 0.05 
was considered statistically significant. Paired t-tests 
were used for the change in physiology measurements 
from sea level to altitude. SAS v9.1 (SAS Institute 
Inc, Cary, NC) was used.
Results
Overall, 246 participants submitted symptom question-
naires and completed baseline medical evaluations. 
Since,  some  symptom  reports  were  incomplete; 
results are reported based only upon complete survey 
results for each question.
environmental conditions
Temperatures at the South Pole averaged −42 ± 1.9 °C 
(−43 °F) during 2006 and −43.3 ± 4.6 °C (−45 °F) 
during  2007  with  an  average  relative  humidity  of 
0.03%  both  years.  Average  barometric  pressures 
during  2006  and  2007  were  512.7  ±  1.4  mmHg 
and  513  ±  4.6  mmHg  respectively  corresponding 
to  equivalent  altitudes  of  3197.4  ±  21.4  meters   
(10,490 feet), and 3183.7 ± 70.1 meters (10,445 feet).   Anderson et al
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The  lowest  average  daily  barometric  pressure 
recordings were 509.8 mmHg (∼3,241.8 m, 10,636 feet) 
during 2006 and 501.8 mmHg (∼3,365.2 m, 11,040 
feet) during 2007.
Baseline subject characteristics
Baseline subject characteristics (Table 1) revealed 
that this group was 70% male with a mean age of 
36.8 ± 10.6 years. Mean BMI was 26.1 ± 4.2 kg/m2 
(women: 25.1 ± 4.8, men: 26.6 ± 3.9). Mean body 
fat was 16.5% ± 6.2% for males and 26.3% ± 7.1% 
for  females.  While  89%  of  the  group  reported 
previous  experience  above  10,000  feet,  the  vast 
majority  of  this  group  (95%)  had  lived  below 
7,500 feet during the last three months. Of those 
with previous high altitude experience, 86% had 
their most recent exposure above 10,000 feet more 
than 4 weeks prior to arrival in Antarctica, 11% 
2–4 weeks ago, and only 2% in the last 2 weeks. In 
this same group with prior altitude exposure, 39% 
reported no prior altitude related health problems 
while 53% reported mild problems and 8% reported 
moderate problems. About half of this group (46%) 
had previously traveled to the South Pole for work 
(Table 1).
general physiology
Physiology test results at McMurdo (sea level) and 
the South Pole revealed increased resting heart rate 
(71.5 ± 12.3 bpm vs. 82.8 ± 13.1 bpm, P , 0.001) 
decreased  oxygen  saturation  (97.3%  ±  1.3%  vs. 
89.1% ± 3.2%, P , 0.001) and decreased average 
systolic  blood  pressure  (111.3  ±  12.5  mmHg  vs. 
105.8 ± 14.8 mmHg, P , 0.001). Hematocrit and 
hemoglobin increased slightly with a small estimated 
reduction  in  blood  and  plasma  volumes  consistent 
with dehydration.11
general symptom patterns and timing
For each of the eleven symptoms recorded, the number 
of participants reporting mild, moderate or severe val-
ues are reported in Table 2. Shortness of breath with 
activity was the most commonly reported symptom 
(87%), followed by sleeping difficulty (74%), head-
ache (66%), fatigue (65%), dizziness/lightheadedness 
(46%) and general health limitation (41%). Trends 
were analyzed for overall symptom reporting (Fig. 
1, Lake Louise Symptoms plus additional questions) 
which were consistent with the Lake Louise Symp-
tom Score (LLSS) peak on Day 2 (LLSS = 2.5 ± 2.1). 
The trends for the four most prominent symptoms 
Table 1. Baseline subject characteristics.
Whole 
group
no acetazolamide Acetazolamide P
Age (years) 36.8 ± 10.6 35.7 ± 9.7 39.1 ± 11.5 0.019
gender, M (%) 168 (70) 94 (69) 63 (69) 0.92
BMI (kg/m2) 26.1 ± 4.2 25.6 ± 3.7 26.7 ± 4.7 0.07
Body fat (%)
  Males 16.5 ± 6.2 15.5 ± 6.0 17.9 ± 6.1 0.015
  Females 26.3 ± 7.1 25.7 ± 7.3 27.5 ± 6.8 0.32
elevation of residence (last 3 months), no. (%) 0.13
 , 5,000 ft above sea level 152 (64) 78 (58) 66 (73)
  5,000–7,500 ft above sea level 74 (31) 49 (36) 21 (23)
  7,500–10,000 ft above sea level 11 (5) 7 (5) 4 (4)
 . 10,000 ft above sea level 1 (0) 1 (1) 0 (0)
Previous altitude exposure (10,000 ft), no. (%) 213 (89) 128 (94) 75 (82) 0.005
Last time at an altitude 10,000 ft, no. (%)
 , 2 weeks ago 5 (2) 4 (3) 1 (1) 0.027
  2 to 4 weeks ago 24 (11) 20 (16) 3 (4)
 . 4 weeks ago 184 (86) 104 (81) 71 (95)
Previous altitude illness (among those with previous exposure), no. (%) 0.006
  no problem 84 (39) 56 (44) 23 (31)
  Mild problem 112 (53) 67 (52) 40 (53)
  Moderate problem 17 (8) 5 (4) 12 (16)
Previously at south pole before, no. (%) 110 (46) 75 (56) 32 (35) 0.003Altitude illness in Antarctica
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reveal persistent reporting of shortness of breath with 
activity and generalized fatigue and to a lesser extent 
difficulty sleeping and headache (Fig. 2).
Acute mountain sickness
Using strict Lake Louise Criteria, 52% of subjects sat-
isfied acute mountain sickness criteria at some point 
during their visit to altitude. On Day 1, 24% met acute 
mountain sickness criteria, and 33% met criteria on Day 
2, with steadily decreasing values on Day 3 (15%), Day 
4 (9%), Day 5 (6%), Day 6 (4%), and Day 7 (4%).
Acetazolamide
Overall, 40% of subjects reported using Acetazolamide 
during the study. Of those reporting Acetazolamide 
usage,  51%  scored  positive  for  acute  mountain 
  sickness versus 52% of those not using Acetazolamide. 
Gender distribution was similar for both groups (69% 
male).  In  general,  those  who  used  acetazolamide 
tended to be older (39.1 ± 11.5 years vs. 35.7 ± 9.7 
years, P = 0.019), report less previous experience at 
altitudes .10,000 ft. (82% vs. 94%, P = 0.005), less 
South Pole experience (35% vs. 56%, P = 0.003) and 
a greater amount of previous mild or moderate prob-
lems with altitude P = 0.006, Table 1).
Discussion
The Antarctic Study of Altitude Physiology exam-
ined  a  large  group  of  working  individuals  rapidly 
  transported the South Pole. The value of this study 
resides in the unique environment, the large,   medically 
screened working population, and the uniform rapid 
ascent of participants to high altitude.
Incidence of acute mountain sickness
Overall,  52%  of  individuals  satisfied  Lake  Louise 
  criteria for acute mountain sickness, which represents 
an incidence of acute mountain sickness higher than 
rapid ascent studies conducted at similar elevations. 
For example, Honigman’s convenience sampling of 
3158 tourists engaging rapid transport to elevations 
between 6700–9200 feet found that 25% of   subjects 
reported  symptoms  consistent  with  a  diagnosis  of 
acute  mountain  sickness.9  The  same  results  were 
obtained when Montgomery et al studied 454 men 
and women at a ski conference at 6,560 ft.12 In 1990, 
Dean  et  al  observed  incidence  of  acute  mountain 
Table 2. Maximum symptom score.
symptom Whole group 
symptomatic
no acetazolamide 
symptomatic
Acetazolamide 
symptomatic
P
no. % no. % no. %
Shortness of breath with activity 213 87 125 89 84 91 0.61
Sleeping difficulty 182 74 109 78 69 75 0.61
headache 162 66 99 71 61 66 0.48
Fatigue 160 65 94 67 64 70 0.70
Dizzy/lightheaded 113 46 68 49 43 47 0.78
general health limitation 99 41 53 38 44 48 0.13
Mental status changes 90 37 48 34 41 45 0.12
Shortness of breath at rest 77 31 43 31 32 35 0.52
Cough 74 30 34 24 37 41 0.008
gI upset 59 24 26 19 31 34 0.009
Peripheral edema 23 9 17 12 6 7 0.16
AMS by Lake Louise criteria 116 52 70 52 46 51 0.87
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Figure 1. Percentage of participants that reached their maximum symptoms 
score for a given day at South Pole. Most participants reached their maxi-
mum symptom score on the first 2 days at altitude, however, .20% of 
subjects, maximum symptoms were reached in days 3–7.Anderson et al
32  Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine  2011:5
sickness  of  42%  in  105  conference  attendees 
rapidly ascending to 10,000 feet.13 The rapid trans-
port experienced by polar workers clearly produces 
incidence  of  acute  mountain  sickness  higher  than 
observations from these other studies of individuals 
rapidly transported to similar altitudes elsewhere on 
the planet (Fig. 3).14
The incidence of altitude illness during the Antarctic 
Study of Altitude Physiology more closely resembles 
studies conducted at higher elevations such as the 
summit of Mauna Kea (4020 m/13,796 ft).15 Onopa 
et al conducted a survey of 198 day visitors and 46 
working astronomers rapidly transported to the summit 
of Mauna Kea observing that 69% of astronomers 
and  30%  of  day  visitors  reported  acute  mountain 
sickness symptoms during their sojourn. Similarly, 
Erba et al found that 52% of mountaineers reported 
acute mountain sickness after a 4–5 hour ascent to 
Capanna Regina Margherita (4559 m/14,957 ft) in 
the  Italian  Dolomites.16  Previous  studies  by  Singh 
indicate that 47% of those rapidly air transported to 
elevations between 3000–5200 m in the Himalayas 
will  be  diagnosed  with  acute  mountain  sickness.17 
Van Patot et al diagnosed acute mountain sickness in 
45% of subjects taking placebo after rapid transport to 
4300 m (14,107 ft).18 These data provide quantitative 
support for the conclusion that the unique features 
of the Antarctic physical environment (hypobarism, 
extreme cold, and low humidity coupled with physical 
exertion)  contribute  to  an  intensified  high  altitude 
exposure  for  polar  workers  when  compared  with 
similar elevations at different geographic locations.
Time course of symptom development
Symptom  reports  at  the  South  Pole  were  mild  to 
moderate  in  severity  with  symptom  prevalence 
peaking  on  the  day  after  arrival  at  high  altitude. 
The Day 2 questionnaire in our study corresponded 
to approximately 12–18 hours after arrival for most 
participants reflecting conventional knowledge that 
symptoms do not appear until 6–48 hours after arrival 
in most people and resolve within the first 2–3 days.19 
Figure 1 shows the peak of symptoms on Day 2 with 
declining values thereafter.
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Figure 2. Severity of most commonly reported symptoms over the first week of exposure in personnel rapidly transported to the South Pole (2835 m, 
9300 ft).Altitude illness in Antarctica
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Rank order of symptoms
Rank  order  of  symptoms  during  this  study  follow 
other reports with exertional dyspnea, sleep disruption, 
headache, and fatigue as the most common symptoms. 
Headache predominates many rank lists from higher 
elevations,20–22 while exertional dyspnea, insomnia, and 
fatigue predominate rank lists at lower elevations.23
Exertional  dyspnea  was  persistently  reported 
throughout our 7 day questionnaire series, while most 
other symptoms followed a steady pattern of decline. 
Exertional dyspnea at altitude most likely represents 
a consequence of exercise in conditions of reduced 
partial pressure of oxygen rather than a maladaptive 
symptom. Since many South Pole workers regularly 
perform heavy physical work, the persistent reporting 
of this symptom may represent their daily experience 
of breathing difficulty as they executed tasks in the 
cold and arid environment of the polar plateau.
Acetazolamide
Acetazolamide did not appear to reduce the incidence 
of acute mountain sickness during this study which 
may indicate difficulties with prophylaxis along with 
self selection of individuals more prone to altitude 
symptoms. Prescription guidelines for acetazolamide 
prophylaxis  presuppose  administration  of  the 
  medication 24–48 hours prior to a   predicted   exposure 
to   altitude.24 The uncertainty of flight schedules in 
  Antarctica  forces  many  individuals  to  begin  the 
medication  on  the  same  day  as  exposure  or  after 
arrival,  possibly  reducing  the  effectiveness  of  the 
treatment. In addition, data suggest that those who 
used acetazolamide were older, had less experience 
at the South Pole, had experienced more moderate 
illness  at  altitude  on  previous  visits,  and  had  less 
experience at the South Pole (Table 1). This self selec-
tion process may have identified individuals who felt 
they had a higher risk of illness based on previous 
experience. If this is true, the use of acetazolamide in 
this group may have reduced their incidence of illness 
to levels experienced by those who declined the use 
of medication.25
Relationship of symptoms  
to physiological measures
A  number  of  physiological  measures  have  been 
thought  to  predict  the  onset  of  AMS.  Examples 
include  a  high  resting  heart  rate  (HR),  low  rest-
ing  and  post-exercise  arterial  oxygen  saturation 
(SaO2),  elevated  BMI,  and  altered  blood  pressure 
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(BP).26–28 We assessed the relationship of resting HR, 
SaO2,  BMI  and  BP  at  SP  with  day  3  LLSS.  Only   
HR  was  significantly,  albeit  mildly  associated  with 
LLSS (R2 = 0.035), indicating only 3.5% of the score 
could be explained by HR (P = 0.01). Based on the 
parameter estimate, a +0.24 increase in LLSS would 
be associated with a +10 bpm change in HR. Oxygen 
saturation did not differ among those with LLSS #2 vs. 
.2 (P = 0.82), while there was a tendency for a lower 
BP to be associated with increased LLSS (P = 0.10).
Polar environment
Physiological data from this study indicate that the 
altitude exposure to workers at the South Pole is more 
intense than would be expected at the same physical 
elevation at more moderate latitudes. Immediate heavy 
exertion,29 extremely low humidity, and cold air30 are 
all suspected to increase the risk of acute mountain 
sickness and HAPE, though the exact mechanisms 
remain unclear. During the 2006 season, 7 workers 
were evacuated from the South Pole for symptoms 
consistent with HAPE. The following season, more 
aggressive intervention with medications and oxygen 
therapy for the most symptomatic individuals at SP 
was pursued.
Limitations
While this study was carefully designed to quantify 
symptoms  in  a  large,  healthy,  non-mountaineering 
cohort, symptom reporting was subjective and may 
reflect environmental factors that are difficult to con-
trol. For example, jet lag and Antarctica’s perpetual 
daylight may have increased the tendency to report 
poor sleep quality at altitude.  However, two weeks 
of circadian adjustment at McMurdo Station probably 
minimized the effect of jet-lag from air travel.  At the 
South  Pole  station,  darkened  sleeping  quarters  also 
reduced the effect of light induced circadian disruption.   
In a similar way uncontrollable environmental factors 
may have exerted minor influence on other subjective 
symptom reports (e.g. headache, shortness of breath).
conclusion
This study at the Amundsen Scott South Pole station 
reveals that over half of polar workers experience 
modest altitude related symptoms for at least 2 days 
after arrival with 20% of individuals having persistent 
symptoms beyond day 3. Shortness of breath with 
activity, sleep difficulties, headache, and fatigue were 
the most prominent symptoms reported, with short-
ness of breath and fatigue being particularly common 
over the course of the initial week. Life threatening 
symptoms occurred in approximately 2% of subjects 
studied at SP. The benefits of acetazolamide appeared 
negligible, though it may have prevented more severe 
symptoms in higher risk subjects. As predicted by 
John West in 2001, the SP constitutes a more intense 
altitude challenge than would be expected based on 
the physical altitude.  This suggests that equivalent 
air altitude (EAA) alone is an inadequate predictor of 
hypoxic stress.
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